Designing βpep peptides: A rational approach to the discovery of novel pharmaceutical agents and small molecules

Drugs of the Future

Volumn 28, Issue 4, 2003, Pages 337-346

  Mayo, Kevin H ^a   Griffioen, Arjan W ^b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ActiPep Biotechnology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGINEX; ANGIOGENESIS INHIBITOR; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; BETA SHEET; BONE MARROW TOXICITY; DRUG DESIGN; DRUG SCREENING; HUMAN; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHARMACOPHORE; PROTEIN FOLDING; REDUCTION; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0038573729     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2003.028.04.740190     Document Type: Review

References (51)

1. Regan, L., DeGrado, W. Characterization of a helical protein designed from first principles. Science 1988, 241: 976-8.
2. DeGrado, W., Wasserman, Z., Lear, J. Protein design, a minimalist approach. Science 1989, 243: 622-8.
3. Hecht, M., Richardson, J., Richardson, D., Ogden, R. De novo design, expression, and characterization of Felix: A four-helix bundle protein of native-like sequence. Science 1990, 249: 884-91.
4. Hahn, K., Klis, W., Stewart, J. Design and synthesis of a peptide having chymotrypsin-like esterase activity. Science 1990, 248: 1544-7.
5. Fedorov, A.N., Dolgikh, D.A., Chemeris, V.V. De novo proteins with a given spatial structure: New approaches to design and analysis. J Mol Biol 1992, 223: 927-31.
6. Richardson, J.S., Richardson, D.C., Tweedy, N.B. et al. Looking at proteins: Representations, folding, packing, and design. Biophys J 1992, 63: 1185-209.
7. Handel, T.M., Williams, S.A., DeGrado, W.F. Metal ion-dependent modulation of the dynamics of a designed protein. Science 1993, 261: 879-85.
8. Kamteker, S., Schiffer, J.M., Xiong, H. et al. Protein design by binary patterning of polar and nonpolar amino acids. Science 1993, 262: 1680-5.
9. Quinn, T.P., Tweedy, N.B., Williams, R.W. et al. βDoublet: De novo design, synthesis and characterization of an β-sandwich protein. Proc Natl Acad Sci USA 1994, 91: 8747-51.
10. Fezoui, J., Weaver, D.L., Osterhout, J.J. De novo design and structural characterization of an α-helical hairpin peptide: A model system for the study of protein folding intermediates. Proc Natl Acad Sci USA 1994, 91: 3675-9.
11. Kuroda, Y., Nakai, T., Ohkubo, T. Solution structure of a de novo helical protein by 2D-NMR spectroscopy. J Mol Biol 1994, 236: 862-8.
12. Bryson, J.W., Betz, S.F., Lu, H.S. et al. Protein design: A hierarchic approach. Science 1995, 270: 935-41.
13. Yan, Y., Erickson, B.W. Engineering of βbellin 14D: Disulfide-induced folding of a β-sheet protein. Protein Sci 1994, 3: 1069-73.
14. Blanco, F.J., Rivas, G., Serrano L. A short linear peptide that folds into a native stable β-hairpin in aqueous solution. Struct Biol 1994, 1: 584-90.
15. Searle, M.S., Williams, D.H., Packman, L.C. A short linear peptide derived from the N-terminal sequence of ubiquitin folds into a water-soluble non-native β-hairpin. Nat Struct Biol 1995, 2: 999-1006.
16. Struthers, M.D., Cheng, R.P., Imperiali, B. Design of a monomeric 23-residue polypeptide with defined tertiary structure. Science 1996, 271: 342-5.
17. Ilyina, E., Mayo, K.H. Multiple native-like conformations trapped via self-association-induced hydrophobic collapse of the 33-residue β-sheet domain from platelet factor 4. Biochem J 1995, 306: 407-19.
18. Mayo, K.H., Ilyina, E., Park, H. A recipe for designing water-soluble, β-sheet-forming peptides. Protein Sci 1996, 5: 1301-15.
19. Richardson, J.S., Richardson, D.C. The de novo design of protein structures. Trends Biochem Sci 1989, 14: 304-9.
20. Ilyina, E., Milius, R., Mayo, K.H. Synthetic peptides probe folding initiation sites in platelet factor-4: Stable chain reversal found within the hydrophobic sequence LIATLKNGRKISL. Biochemistry 1994, 33: 13436-44.
21. Ilyina, E., Roongta, V., Mayo, K.H. NMR structure of a de novo designed peptide 33mer with two distinct, compact beta-sheet folds. Biochemistry 1997, 36: 5245-50.
22. Miller, M.D., Krangel, M.S. Biology and biochemistry of the chemokines: A family of chemotactic and inflammatory cytokines. Crit Rev Immunol 1992, 12: 17-46.
23. Mayo, K.H., van der Schaft, D.W.J., Griffioen, A.W. Designed β-sheet peptides that inhibit proliferation and induce apoptosis in endothelial cells. Angiogenesis 2001, 4: 45-51.
24. Mayo, K.H., Ilyina, E. A folding pathway for βpep-4 peptide 33mer: From unfolded monomers and β-sheet sandwich to well-structured tetramers. Protein Sci 1998, 7: 358-68.
25. Gray, B.H., Haseman, J.R., Mayo, K.H. B/PI-derived synthetic peptides: Synergistic effects in tethered bactericidal and endotoxin neutralizing peptides. Biochim Biophys Acta 1995, 244: 185-90.
26. Little, R.G., Kelner, D.N., Lim, E. et al. Functional domains of recombinant bactericidal/permeability increasing protein (rBPI23). J Biol Chem 1994, 269: 1865-72.
27. Mayo, K.H., Haseman, J., Ilyina, E., Gray, B. Designed βsheet-forming peptide 33mers with potent human bactericidal/permeability increasing protein-like bactericidal and endotoxin neutralizing activities. Biochem Biophys Acta 1998, 1425: 81-92.
28. Beamer, L.J., Carroll, S.F., Eisenberg, D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science 1997, 276: 1861-4.
29. Uknis, M.R., Wasiluk, K.R., Acton, R.D. et al. Design of a potent novel endotoxin antagonist. Surgery 1997, 122: 380-5.
30. Mayo, K.H., Haseman, J., Young, H.C. and Mayo, J.W. Structure-function relations in novel peptide dodecamers with broad spectrum bactericidal and endotoxin neutralizing activities. Biochem J 2000, 349: 717-28.
31. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1: 27-31.
32. Griffioen, A.W., Molema, G. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000, 52: 237-68.
33. Gupta, S.K., Hassel, T., Singh, J.P. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Natl Acad Sci USA 1995, 92: 7799-803.
34. Tolsma, S.S., Volpert, O.V., Good, D.J. et al. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 1993, 122: 497-511.
35. Luster, A.D., Greenberg, S.M., Leder, P. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 1995, 182: 219-31.
36. O'Reilly, M.S., Holmgren, L., Shing, Y. et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79: 315-28.
37. O'Reilly, M.S., Boehm, T., Shing, Y. et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88: 277-85.
38. Pike, S.E., Yao, L., Jones, K.D. et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998, 188: 2349-56.
39. Van der Schaft, D.W.J., Toebes, E.A.H., Haseman, J.R. et al. Bactericidal/permeability increasing protein (BPI) inhibits angiogenesis via induction of apoptosis in vascular endothelial cells. Blood 2000, 96: 176-81.
40. Hohenester, E., Sasaki, T., Olsen, B.R., Timpl, R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J 1998, 17: 1656-64.
41. Mayo, K.H., Roongta, V., Barker, S. et al. NMR solution structure of the 32 kD tetrameric platelet factor-4 ELR-motif N-terminal chimer: A symmetric tetramer. Biochem 1995, 34: 11399-409.
42. Jones, E.Y., Stuart, E.D., Walker, N.P.C. Structure of tumor necrosis factor. Nature 1989, 338: 225-8.
43. Griffioen, A.W., van der Schaft, D., Barandsz-Janson, A. et al. Anginex, a designed peptide that inhibits angiogenesis. Biochem J 2001, 354: 233-42.
44. van der Schaft, D.W.J., Dings, R.P.M., de Lussanet, Q.R. et al. The designer antiangiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J 2002, 16: 1991-3.
45. Lichtenbeld, H., Barendsz-Janson, A.F., Van Essen, H. et al. Human tissue hetero-transplantations in an in vivo angiogenesis model. Int J Cancer 1998, 77: 455-9.
46. Dings, R.P.M., Hargittai, B., Haseman, J. et al. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett 2002, in press.
47. Dings, R.P.M., Yokoyama, Y., Ramakrishnan, S. et al. The designed angiostatic peptide anginex synergistically improves chemotherapy and anti-angiogenesis therapy with angiostatin. Cancer Res 2003, 63: 382-5.
48. Griffioen, A., Damen, C., Martinotti, S. et al. Angiogenesis inhibitors overcome tumor-induced endothelial cell anergy. Int J Cancer 1999, 80: 315-9.
49. Tromp, S.C., Oude Egbrink, M.G., Slaaf, D. et al. Tumor angiogenesis factors reduce leukocyte adhesion in vivo. Int Immunol 2000, 12: 671-6.
50. Gupta, S.K., Singh, J.P. Inhibition of endothelial cell proliferation by platelet factor-4 involves a unique action on S phase progression. J Cell Biol 1994, 127: 1121-7.
51. Slungaard, A., Key, N.S. Platelet factor 4 stimulates thrombomodulin protein C-activating cofactor activity. A structure-function analysis. J Biol Chem 1994, 269: 25549-56.